Rani Therapeutics Holdings, Inc. (RANI)

Nasdaq: RANI · Pharmaceutical Preparations · San Jose, CA · filing with the SEC since 2021

Full chart Alerts Compare

Grade3.8

◀ Past 3.3● Present 3.2▶ Future 4.5

3 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Rani Therapeutics Holdings, Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.8/10

◀ Past3.325% of the headline

● Present3.235% of the headline

▶ Future4.540% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.3/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

1.5/10

Has it survived what it has been through?

7 warning events since 2021; the latest 2026-11-12.

weight 22% of this tense · 15th percentile among 497 sector filers · read for itself

From the record

Rani Therapeutics Holdings, Inc.'s filings since 2021 show 7 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2026-11-12); an auditor change (8-K item 4.01, 2 times, the latest 2025-04-09); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2021-11-16) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

4.1/10

What has it actually done, year after year?

+28.7% a year over 6 filed years; profitable in 0 of 3.

weight 45% of this tense · 41st percentile among 323 sector filers · read for its customers

From the record

Rani Therapeutics Holdings, Inc.'s 6 filed years say what it did: revenue went from $462 thousand in fiscal 2020 to $2 million in fiscal 2025, up 28.7% a year; it rose in 2 of 3 years; the deepest fall was 100% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 3 of those years (its annual reports).

What it rests on

revenue growth over the filed span28.7%top 32% of its family
the share of years revenue rosetop 41% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

3.5/10

How has it treated the people who own it?

SI estimate 3.5/10, confidence 35 of 100 (one part).

weight 33% of this tense · 35th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 35% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Rani Therapeutics Holdings, Inc.'s shareholder treatment is put at 3.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 35% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.2/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

3.0/10

Is it financially healthy right now?

Leverage 44%: owes 44¢ per asset dollar.

weight 45% of this tense · 30th percentile among 473 sector filers · read for itself

From the record

Leverage: it owed about 44 cents per dollar of assets, and net share issuance: its share count grew 132.3% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 40% of its family
the share count against the year beforebottom 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

SI estimate

2.7/10

How strong is its position in its industry?

SI estimate 2.7/10, confidence 35 of 100 (one part).

weight 22% of this tense · 27th percentile among 318 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, revenue against the family, which ranks in the bottom 27% of 318 in its family; fewer than two of the three parts can be read: size in the family's currency, net margin, three-year growth.
What the record cannot read: Fewer than two of the three parts can be read: size in the family's currency, net margin, three-year growth.
How it was reasoned: one part: revenue against the family, the one part on file, ranked among 318 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Rani Therapeutics Holdings, Inc.'s industry position is put at 2.7 of 10 with a confidence of 35 of 100, because read from one part only, revenue against the family, which ranks in the bottom 27% of 318 in its family; fewer than two of the three parts can be read: size in the family's currency, net margin, three-year growth. A filing that carries the missing parts replaces this estimate with the filed reading.

Leadership

as filed

3.7/10

What are the people in charge doing?

bottom 37% of 315 in its family for leadership; chief executive since 2021.

weight 33% of this tense · 37th percentile among 315 sector filers · read for its shareholders

From the record

Rani Therapeutics Holdings, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Imran, Talat (Chief Executive Officer, as filed), filing under that title since 2021-07-29, 5.3 years (top 48% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 3.3 years (bottom 18%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 40%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge6 in three years among 11 peoplebottom 40% of its family
the median years the people in charge have filed3.3 yearsbottom 18% of its family
the chief executive's years on the record5.3 yearstop 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.5/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed

5.3/10

How much room does it have to grow?

top 47% of 273 in its family for room to expand.

weight 33% of this tense · 53rd percentile among 273 sector filers · read for itself

From the record

Rani Therapeutics Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $19 million against debt of $0 thousand leaves 31.8% of its assets as net cash, top 46% of its family; cash from operations less capital spending is -1151.4% of revenue (bottom 23%); research spending of 1237.3% of revenue (top 19%) (its annual report).

What it rests on

cash less debt against assets31.8%top 46% of its family
cash from operations less capital spending against revenue-1151.4%bottom 23% of its family
research spending against revenue1237.3%top 19% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

3.6/10

What could actually drive growth from here?

bottom 36% of 306 in its family for growth drivers.

weight 45% of this tense · 36th percentile among 306 sector filers · read for its customers

From the record

Rani Therapeutics Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 58.9% (top 23%); research spending grew -18% a year (bottom 20%); capital spending grew -62.1% a year (bottom 12%) (its annual reports). Rani Therapeutics Holdings, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

the newest year's revenue growth58.9%top 23% of its family
three-year growth of research spending-18.0%bottom 20% of its family
three-year growth of capital spending-62.1%bottom 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Rani Therapeutics Holdings, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton RANI · research, not advice